BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 33429396)

  • 1. Evaluation of Alitretinoin for the Treatment of Mycosis Fungoides and Sézary Syndrome.
    Alhusayen R; Vu TT; Almuhanna N; Wohlmuth-Wieser I; Hardin J; Hughes JM; Chia J; Street L; Shear NH; Walsh SR; Gniadecki R
    Dermatology; 2021; 237(3):479-485. PubMed ID: 33429396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alitretinoin in the treatment of cutaneous T-cell lymphoma.
    Kaemmerer T; Stadler PC; Helene Frommherz L; Guertler A; Einar French L; Reinholz M
    Cancer Med; 2021 Oct; 10(20):7071-7078. PubMed ID: 34435474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous T-cell lymphomas (CTCL) (Mycosis fungoides and Sézary syndrome).
    Dummer R; Duvic M; Scarisbrick J; Olsen EA; Rozati S; Eggmann N; Goldinger SM; Hutchinson K; Geskin L; Illidge TM; Giuliano E; Elder J; Kim YH
    Ann Oncol; 2014 Sep; 25(9):1807-1812. PubMed ID: 24948692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of cutaneous T-cell lymphoma with oral alitretinoin.
    Kapser C; Herzinger T; Ruzicka T; Flaig M; Molin S
    J Eur Acad Dermatol Venereol; 2015 Apr; 29(4):783-8. PubMed ID: 25175592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bexarotene therapy for mycosis fungoides and Sézary syndrome.
    Abbott RA; Whittaker SJ; Morris SL; Russell-Jones R; Hung T; Bashir SJ; Scarisbrick JJ
    Br J Dermatol; 2009 Jun; 160(6):1299-307. PubMed ID: 19222457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of advanced mycosis fungoides/Sézary syndrome with fludarabine and potential adjunctive benefit to subsequent extracorporeal photochemotherapy.
    Quaglino P; Fierro MT; Rossotto GL; Savoia P; Bernengo MG
    Br J Dermatol; 2004 Feb; 150(2):327-36. PubMed ID: 14996105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study.
    Querfeld C; Thompson JA; Taylor MH; DeSimone JA; Zain JM; Shustov AR; Johns C; McCann S; Lin GHY; Petrova PS; Uger RA; Molloy N; Shou Y; Akilov OE
    Lancet Haematol; 2021 Nov; 8(11):e808-e817. PubMed ID: 34627593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current systemic therapeutic options for advanced mycosis fungoides and Sézary syndrome.
    Janiga J; Kentley J; Nabhan C; Abdulla F
    Leuk Lymphoma; 2018 Mar; 59(3):562-577. PubMed ID: 29308723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mycosis fungoides and Sezary syndrome: therapeutic approach and outcome in 113 patients.
    Anadolu RY; Birol A; Sanli H; Erdem C; Türsen U
    Int J Dermatol; 2005 Jul; 44(7):559-65. PubMed ID: 15985024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extracorporeal Photopheresis in the Treatment of Mycosis Fungoides and Sézary Syndrome.
    Zic JA
    Dermatol Clin; 2015 Oct; 33(4):765-76. PubMed ID: 26433848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polish Lymphoma Research Group Experience With Bexarotene in the Treatment of Cutaneous T-Cell Lymphoma.
    Sokolowska-Wojdylo M; Florek A; Zaucha JM; Chmielowska E; Giza A; Knopinska-Posluszny W; Kulikowski W; Prejzner W; Romejko-Jarosinska J; Paszkiewicz-Kozik E; Osowiecki M; Walewski J; Rogowski W; Grzanka A; Placek W; Lugowska-Umer H; Kowalczyk A; Nowicki R; Jurczak W
    Am J Ther; 2016; 23(3):e749-56. PubMed ID: 24732904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of mogamulizumab in patients with Mycosis Fungoides or Sézary syndrome: A multicentre, retrospective, real-world French study.
    Beylot-Barry M; Quereux G; Nardin C; Duval-Modeste AB; Dereure O; Dalac-Rat S; Dobos G; Pham-Ledard A; Ram-Wolff C; D'Incan M; Grange F; Braniste V; Bagot M
    J Eur Acad Dermatol Venereol; 2023 Sep; 37(9):1777-1784. PubMed ID: 37113040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measurement of Quality of Life in Patients with Mycosis Fungoides/Sézary Syndrome Cutaneous T-Cell Lymphoma: Development of an Electronic Instrument.
    McCaffrey S; Black RA; Nagao M; Sepassi M; Sharma G; Thornton S; Kim YH; Braverman J
    J Med Internet Res; 2019 Jan; 21(1):e11302. PubMed ID: 30617041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experience With Bexarotene to Treat Cutaneous T-Cell Lymphomas: A Study of the Spanish Working Group of Cutaneous Lymphomas.
    Izu-Belloso R; Gainza-Apraiz I; Ortiz-Romero P; Servitje-Bedate O; Fernández de Misa-Cabrera R; Peñate Y; Hernandez-Machin B; Estrach-Panella T; Llamas-Velasco M; Yanguas-Bayona JI; Morillo-Andujar M; Acebo-Mariñas E; Perez-Gala S; Armario-Hita JC; Sanchez-Sambucety P; Ortiz-Brugues A; Eguren-Michelena C; Bielsa-Marsol I; Lopez-Pestaña A; Blanes-Martinez M; Fernandez-Guarino M; Lopez-Lerma I
    Actas Dermosifiliogr; 2024 Jun; 115(6):T547-T554. PubMed ID: 38653368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experience With Bexarotene to Treat Cutaneous T-Cell Lymphomas: A Study of the Spanish Working Group of Cutaneous Lymphomas.
    Izu-Belloso R; Gainza-Apraiz I; Ortiz-Romero P; Servitje-Bedate O; Fernández de Misa-Cabrera R; Peñate Y; Hernandez-Machin B; Estrach-Panella T; Llamas-Velasco M; Yanguas-Bayona JI; Morillo-Andujar M; Acebo-Mariñas E; Perez-Gala S; Armario-Hita JC; Sanchez-Sambucety P; Ortiz-Brugues A; Eguren-Michelena C; Bielsa-Marsol I; Lopez-Pestaña A; Blanes-Martinez M; Fernandez-Guarino M; Lopez-Lerma I
    Actas Dermosifiliogr; 2024 Jun; 115(6):547-554. PubMed ID: 38395224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spotlight on Mogamulizumab-Kpkc for Use in Adults with Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome: Efficacy, Safety, and Patient Selection.
    Blackmon AL; Pinter-Brown L
    Drug Des Devel Ther; 2020; 14():3747-3754. PubMed ID: 32982179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relevance of peripheral blood T-helper 1 and 2 cytokine pattern in the evaluation of patients with mycosis fungoides and Sézary syndrome.
    Papadavid E; Economidou J; Psarra A; Kapsimali V; Mantzana V; Antoniou C; Limas K; Stratigos A; Stavrianeas N; Avgerinou G; Katsambas A
    Br J Dermatol; 2003 Apr; 148(4):709-18. PubMed ID: 12752128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acitretin for the treatment of cutaneous T-cell lymphoma.
    Cheeley J; Sahn RE; DeLong LK; Parker SR
    J Am Acad Dermatol; 2013 Feb; 68(2):247-54. PubMed ID: 22917895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brentuximab as a treatment for CD30+ mycosis fungoides and Sézary syndrome.
    Mehra T; Ikenberg K; Moos RM; Benz R; Nair G; Schanz U; Haralambieva E; Hoetzenecker W; Dummer R; French LE; Guenova E; Cozzio A
    JAMA Dermatol; 2015 Jan; 151(1):73-7. PubMed ID: 25317818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.